AUROPHARMA

What Aurobindo Pharma promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 20 tracked 4 delivered 3 missed 13 open
  • M&A Closure Timeline delivered said Q1 FY26 Promised: 9 months as a matter of abundant caution (by Q4 FY26) Q1 FY27: Successfully completed the acquisition during Q1 FY27, ahead of the revised 'early Q2' timeline.
  • EBITDA Margin missed said Q3 FY25 Promised: 21% to 22% for FY25 Q1 FY27: Promise relates to FY25 and is concluded. Not discussed.
  • Business Inflection Year on track said Q3 FY25 Promised: 2028 to 2030 will be the inflection point Q1 FY27: Progress continues with imminent US filings and 4 approvals in EU/UK/Canada. Management reiterated target of 7-8 products by 2028-29.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 20 tracked commitments for Aurobindo Pharma — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens